摘要
Hepatocellular carcinoma(HCC),as one of the most com-mon types of primary liver cancer(PLV),accounts for approximately 75%e90%of all PLV cases identified worldwide.^(1)Currently,the most effective treatment for HCC patients constitutes liver transplantation.However,due to high rates of recurrence a poor prognosis is predicted.^(2)Therefore,accurate HCC biomarkers are ur-gently needed to develop innovative therapeutics.Most of earlier investigations to identify biomarkers have been severely limited by sample size.
基金
support from Kerman University of Medical Sciences,Kerman,Iran(No.98000927)
approved by the Ethics Committee of Kerman University of Medical Sciences(Iran)(No.IR.KMU.REC.1399.116).
